ArticleChemistry & biodiversity2026
Anti-Inflammatory Effects of Vicatia thibetica De Boiss. in Rheumatoid Arthritis and Associated Multi-Pathway Modulation In Vivo.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Vicatia thibetica de Boiss. (VTDB) is not only used as an important Tibetan medicine but is also consumed as a common wild vegetable. Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent synovial inflammation and progressive destruction of cartilage and bone. VTDB is recorded in the Four Medical Classics for treating "Huang-Shui," a condition resembling RA. To preliminarily investigate its potential therapeutic basis, VTDB and its polarity-based fractions were evaluated for their effects against RA. The chemical constituents of VTDB-TE were profiled using UHPLC-Q-Orbitrap MS/MS, and network pharmacology analysis predicted possible involvement of the PI3K/Akt and JAK2/STAT3 signaling pathways. Among the tested fractions, VTDB-nBuOH exhibited the most pronounced pharmacological activity in the collagen-induced arthritis (CIA) rat model. VTDB-nBuOH treatment was associated with reduced paw swelling, lower serum levels of rheumatoid factor (RF) and C-reactive protein (CRP), and improved synovial histopathology. The treatment was also associated with reduced levels of pro-inflammatory cytokines and alterations in the levels of proteins associated with PI3K/Akt, JAK2/STAT3, and the downstream IKK/IκB/NF-κB axis. Additionally, VTDB-nBuOH treatment was associated with a shift in macrophage polarization markers toward an anti-inflammatory M2-like phenotype, suggesting a possible restoration of the M1/M2 balance within the joint microenvironment. 16S rRNA sequencing revealed VTDB-nBuOH treatment-associated changes in gut microbial composition, including enrichment of certain beneficial genera and reduction of some pathogenic taxa. Proteomic analysis also pointed to the PI3K/Akt pathway as a potential node of interest. Collectively, these correlative findings suggest that VTDB-nBuOH may alleviate synovial inflammation and cartilage and bone damage through multi-pathway modulation, though further mechanistic studies are needed to establish causality. VTDB-nBuOH shows preliminary promise for further investigation as a potential candidate for RA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.